Literature DB >> 17429138

Pathology databanking and biobanking in The Netherlands, a central role for PALGA, the nationwide histopathology and cytopathology data network and archive.

M Casparie1, A T M G Tiebosch, G Burger, H Blauwgeers, A van de Pol, J H J M van Krieken, G A Meijer.   

Abstract

Since 1991, a nationwide histopathology and cytopathology network and archive is in operation in The Netherlands under the name PALGA, encompassing all sixty-four pathology laboratories in The Netherlands. The overall system comprises decentralized systems at the participating laboratories, a central databank, and a dedicated communication and information exchange tool. Excerpts of all histopathology and cytopathology reports are generated automatically at the participating laboratories and transferred to the central databank. Both the decentralized systems and the central system perform checks on the quality and completeness of excerpts. Currently, about 42 million records on almost 10 million patients are stored in the central databank. Each excerpt contains patient identifiers, including demographic data and the so-called PALGA diagnosis. The latter is structured along five classification axes: topography, morphology, function, procedure, and diseases. All data transfer and communication occurs electronically with encryption of patient and laboratory identifiers. All excerpts are continuously available to all participating pathology laboratories, thus contributing to the quality of daily patient care. In addition, external parties may obtain permission to use data from the PALGA system, either on an ongoing basis or on the basis of a specific permission. Annually, 40 to 60 applications for permission to use PALGA data are submitted. Among external users are the Dutch cancer registry, population-based screening programs for cancer of the uterine cervix and breast cancer in The Netherlands, and individual investigators addressing a range of research questions. Many scientific papers and theses incorporating PALGA data have been published already. In conclusion, the PALGA system is a unique system that requires a minimal effort on the part of the participating laboratories, while providing them a powerful tool in their daily practices.

Entities:  

Mesh:

Year:  2007        PMID: 17429138      PMCID: PMC4618410          DOI: 10.1155/2007/971816

Source DB:  PubMed          Journal:  Cell Oncol        ISSN: 1570-5870            Impact factor:   6.730


  231 in total

1.  Stratification based on methylation of TBX2 and TBX3 into three molecular grades predicts progression in patients with pTa-bladder cancer.

Authors:  Willemien Beukers; Raju Kandimalla; Roy G Masius; Marcel Vermeij; Ries Kranse; Geert Jlh van Leenders; Ellen C Zwarthoff
Journal:  Mod Pathol       Date:  2014-11-14       Impact factor: 7.842

2.  Long-Term Risk of Skin Cancer Among Childhood Cancer Survivors: A DCOG-LATER Cohort Study.

Authors:  Jop C Teepen; Judith L Kok; Leontien C Kremer; Wim J E Tissing; Marry M van den Heuvel-Eibrink; Jacqueline J Loonen; Dorine Bresters; Helena J van der Pal; Birgitta Versluys; Eline van Dulmen-den Broeder; Tamar Nijsten; Michael Hauptmann; Nynke Hollema; Wil V Dolsma; Flora E van Leeuwen; Cécile M Ronckers
Journal:  J Natl Cancer Inst       Date:  2019-08-01       Impact factor: 13.506

3.  Cervix smear abnormalities: linking pathology data in female twins, their mothers and sisters.

Authors:  Jacqueline M Vink; Folkert J van Kemenade; Chris J L M Meijer; Mariel K Casparie; Gerrit A Meijer; Dorret I Boomsma
Journal:  Eur J Hum Genet       Date:  2010-08-18       Impact factor: 4.246

Review 4.  Borrelial fasciitis: as yet insufficient proof for a distinct entity.

Authors:  Pieternella Maria Houtman; Tim L Jansen; Jan Weel; Joris K A Grond
Journal:  Rheumatol Int       Date:  2009-06-09       Impact factor: 2.631

5.  Archiving the phenome: clinical records deserve long-term preservation.

Authors:  Milton Corn
Journal:  J Am Med Inform Assoc       Date:  2008-10-24       Impact factor: 4.497

6.  Promoter Methylation of CDO1 Identifies Clear-Cell Renal Cell Cancer Patients with Poor Survival Outcome.

Authors:  Ivette A G Deckers; Leo J Schouten; Leander Van Neste; Iris J H van Vlodrop; Patricia M M B Soetekouw; Marcella M L L Baldewijns; Jana Jeschke; Nita Ahuja; James G Herman; Piet A van den Brandt; Manon van Engeland
Journal:  Clin Cancer Res       Date:  2015-04-22       Impact factor: 12.531

7.  Assessment of Cutaneous Squamous Cell Carcinoma (cSCC) In situ Incidence and the Risk of Developing Invasive cSCC in Patients With Prior cSCC In situ vs the General Population in the Netherlands, 1989-2017.

Authors:  Selin Tokez; Marlies Wakkee; Marieke Louwman; Eline Noels; Tamar Nijsten; Loes Hollestein
Journal:  JAMA Dermatol       Date:  2020-09-01       Impact factor: 10.282

8.  Lymphadenectomy and Adjuvant Therapy Improve Survival with Uterine Carcinosarcoma: A Large Retrospective Cohort Study.

Authors:  Marco A C Versluis; Cindy Pielsticker; Maaike A van der Aa; Marco de Bruyn; Harry Hollema; Hans W Nijman
Journal:  Oncology       Date:  2018-05-23       Impact factor: 2.935

9.  Reliability of self-reported diagnostic radiation history in BRCA1/2 mutation carriers.

Authors:  Anouk Pijpe; Peggy Manders; Renée L Mulder; Flora E van Leeuwen; Matti A Rookus
Journal:  Eur J Epidemiol       Date:  2010-02       Impact factor: 8.082

10.  Inguinal endometriosis, a rare entity of which surgeons should be aware: clinical aspects and long-term follow-up of nine cases.

Authors:  N Wolfhagen; N E Simons; K H de Jong; P J M van Kesteren; M P Simons
Journal:  Hernia       Date:  2018-08-04       Impact factor: 4.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.